daglutril
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2004 (NCT00160212)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Endothelin-converting enzyme 1INHIBITOR
ECE1 inhibitor
- NeprilysinINHIBITOR
inhibitor - neutral endopeptidase
- Endothelin-converting enzyme 1INHIBITOR
Endothelin-converting enzyme 1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)[C@H](CCCc1ccccc1)C1(C(=O)N[C@H]2CCc3ccccc3N(CC(=O)O)C2=O)CCCC1- Mol. weight
- 534.65 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL3989794 ↗
- ChEMBLCHEMBL2107738 ↗
Also known as
- ((3s)-3-{1-((2r)-2-ethoxycarbonyl-4-phenylbutyl)cyclopentanecarboxamido}-2-oxo-2,3,4,5-tetrahydro-1h-1-benzazepin-1-yl)acetic acid
- ((3s)-3-{1-((2r)-2-ethoxycarbonyl-4-phenylbutyl)cyclopentanecarboxamido}-2-oxo-2,3,4,5-tetrahydro-1h-1-benzazepin-1-yl)acetic acid
- daglutril
- daglutril
- daglutril
- daglutril
- daglutril
- slv306
- slv 306
- slv-306
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00160225 | Phase 2 | Jul 1, 2005 | Solvay |
| NCT00160212 | Phase 2 | Dec 1, 2004 | Solvay |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Solvay | For profit | 2 | 2 | 1 | 2004 |
1 organizations
Page 1 / 1